Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack.
National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.
In a preliminary study, Johns Hopkins Medicine researchers report that as many as a third of those with "wet" age-related macular degeneration may someday be able to safely stop eye injection therapy without further vision loss.
Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.
Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).
Using a stem-cell-derived model, researchers have identified two drug candidates that may slow dry age-related macular degeneration (AMD), a leading cause of blindness for which no treatment exists.